Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06687603 · ClinicalTrials.gov registry record · NA
Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms
A NA study of Esophageal Adenocarcinoma and Gastroesophageal Reflux, sponsored by Case Comprehensive Cancer Center.
- Recruiting
- Registry status
- NA
- Development phase
- 800
- Enrollment target
- 5
- Study locations
NCT06687603: Recruiting NA study of Esophageal Adenocarcinoma and Gastroesophageal Reflux, sponsored by Case Comprehensive Cancer Center.
NCT06687603 is a NA study of Esophageal Adenocarcinoma and Gastroesophageal Reflux that is actively recruiting participants, run by Case Comprehensive Cancer Center. The registered enrollment target is 800 participants, above the 290-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (176% higher). The trial reports 5 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06687603, a NA study of Esophageal Adenocarcinoma and Gastroesophageal Reflux, is actively recruiting participants, sponsored by Case Comprehensive Cancer Center.
- RECRUITING
- Registry status
- NA
- Development phase
- 800 participants
- Enrollment target
- 5
- Study locations
Study Summary
The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged by acid reflux. The main question it aims to answer is: Can this approach demonstrate efficacy for screening of Barrett's esophagus? Participants will: * Participate in a questionnaire. * Undergo a capsule balloon test, called EsoCheck. * Have their EsoCheck sample sent to the laboratory for an EsoGuard test, which is used to detect Barrett's esophagus. * Participants will undergo upper endoscopy as part of standard of care.
Primary Outcome
The primary goal of this study is to develop a non-endoscopic screening test for the non-GERD population that provides a PPV \>20%, i.e. at least 2-fold greater than the 10% PPV of society recommended EGD screening of chronic GERD patients with any additional risk factors.
Conditions Studied
Interventions
- DEVICE EsoCheck
- DIAGNOSTIC_TEST EsoGuard
Study Locations (5)
Ohio
- University Hospitals Cleveland Medical Center - Cleveland
- Cleveland Clinic Taussig Cancer Center - Cleveland
Colorado
- University of Colorado - Aurora
Maryland
- Johns Hopkins Hospital - Baltimore
North Carolina
- University of North Carolina at Chapel Hill - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 800 participants |
| Start Date | 2025-03-10 |
| Est. Completion | 2029-09-27 |
| Phase | NA |
What NCT06687603 shows while recruiting
NCT06687603 is an interventional study that assigns participants to a tested intervention. The registered 800 participants enrollment target is mid-sized for trials with a published cap, above the 290-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (176% higher).
The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 2 interventions - of which EsoCheck is the first listed.
NCT06687603 lists 5 locations in 4 states (Ohio, Colorado, Maryland).
Frequently Asked Questions
What is clinical trial NCT06687603 about?
NCT06687603 is a clinical study titled "Multi-Site Detection of Barrett's Esophagus in Patients Without Chronic GERD Symptoms". The goal of this clinical trial is to develop a method to detect Barrett's esophagus in individuals with a new office based diagnostic test. Barrett's esophagus is a condition in which the flat pink lining of the swallowing tube that connects the mouth to the stomach (the esophagus) becomes damaged ...
What is the current status of trial NCT06687603?
This trial is currently recruiting. It is a NA study. The enrollment target is 800 participants. The study started on 2025-03-10. Estimated completion is 2029-09-27.
What conditions does trial NCT06687603 study?
This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Gastroesophageal Reflux, Barrett Esophagus.
What interventions are being tested in trial NCT06687603?
The interventions under investigation include: EsoCheck (DEVICE), EsoGuard (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT06687603?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06687603 being conducted?
This trial has 5 study locations across Colorado, Maryland, North Carolina, Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Esophageal Adenocarcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06687603's enrollment target sits among peer trials
800 5th of 43 higher than 39 of 43 other Esophageal Adenocarcinoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Esophageal Adenocarcinoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Minimally Invasive Molecular Approaches for the Diagnosis of Barrett's Esophagus and Esophageal Adenocarcinoma
RECRUITING · NA
-
Assessment of a Minimally Invasive Collection Device for Molecular Analysis of Esophageal Samples
RECRUITING · NA
-
Seattle Biopsy Protocol Versus Wide-Area Transepithelial Sampling in Patients With Barrett's Esophagus Undergoing Surveillance
RECRUITING · NA
-
Surveillance vs. Endoscopic Therapy for Barrett's Esophagus With Low-grade Dysplasia
RECRUITING · NA
-
Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome
COMPLETED · NA
-
Esophageal Cytology With FISH in Detecting Esophageal Cancer
COMPLETED · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00695214 · 800 participants · Phase 2
Drug-Induced Sleep Endoscopy for Upper Airway Evaluation in Obstructive Sleep Apnea
- NCT03048201 · 800 participants · NA
Physica System Total Knee Replacement Registry Study
- NCT03792659 · 800 participants
The EXPLORE MG Registry for Myasthenia Gravis
- NCT03819296 · 800 participants · Phase 1
Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI